Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drotrecogin alfa - Eli Lilly

Drug Profile

Drotrecogin alfa - Eli Lilly

Alternative Names: Activated-protein-C; Activated-protein-C - Eli-Lilly; DrotAA; Drotrecogin-alfa-activated; Drotrecogin-alpha; LTC-203; LY 203638; Recombinant human activated protein C; rhAPC; Xigris

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Georgetown University; Syncor; Teijin Pharma
  • Class Anticoagulants; Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins
  • Mechanism of Action Fibrinolytic agents; Serine endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Septic shock
  • Discontinued Thrombosis

Most Recent Events

  • 25 Oct 2011 Discontinued - Phase-I for Septic shock in Japan (IV)
  • 25 Oct 2011 Discontinued - Registered for Septic shock in Colombia (IV)
  • 25 Oct 2011 Discontinued - Registered for Septic shock in Peru (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top